INmune Bio, Inc. (NASDAQ:INMB) Receives $18.00 Average Price Target from Analysts

Shares of INmune Bio, Inc. (NASDAQ:INMB) have earned a consensus rating of “Hold” from the seven brokerages that are currently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $18.00.

A number of research firms have commented on INMB. Wall Street Zen upgraded shares of INmune Bio from a “sell” rating to a “hold” rating in a research note on Sunday, December 14th. Weiss Ratings reissued a “sell (e+)” rating on shares of INmune Bio in a research note on Wednesday, October 8th.

INmune Bio Stock Performance

Shares of INMB opened at $1.73 on Friday. INmune Bio has a fifty-two week low of $1.38 and a fifty-two week high of $11.64. The firm has a market cap of $45.98 million, a price-to-earnings ratio of -0.82 and a beta of 0.70. The firm has a 50 day moving average price of $1.68 and a 200-day moving average price of $1.99.

INmune Bio (NASDAQ:INMB) last released its quarterly earnings results on Thursday, October 30th. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.07. As a group, equities research analysts predict that INmune Bio will post -2.24 earnings per share for the current year.

Institutional Trading of INmune Bio

Several hedge funds have recently made changes to their positions in INMB. Intech Investment Management LLC purchased a new position in INmune Bio in the 2nd quarter worth about $26,000. PFG Investments LLC bought a new position in shares of INmune Bio during the 2nd quarter worth about $27,000. Cary Street Partners Financial LLC bought a new stake in INmune Bio in the 3rd quarter valued at $29,000. Squarepoint Ops LLC bought a new position in shares of INmune Bio during the third quarter valued at $30,000. Finally, Independent Advisor Alliance acquired a new stake in INmune Bio in the 3rd quarter valued at about $30,000. Institutional investors and hedge funds own 12.72% of the company’s stock.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.